Parainfluenza Virus in the Hospitalized Adult

Elliott Russell, Michael G Ison*

*Corresponding author for this work

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Parainfluenza virus (PIV) is a negative-sense single-stranded RNA virus in the Paramyxoviridae family. There are 4 serotypes that follow seasonal patterns with varying rates of infection for each serotype. PIV is an established cause of disease and death in the pediatric and immunocompromised populations, and its impact on the hospitalized adult is becoming more apparent with the increased use of multiplex molecular assays in the clinical setting. The clinical presentation of PIV in hospitalized adults varies widely and includes upper respiratory tract infections, severe lower respiratory tract infections, and exacerbations of underlying disease; 0.2%-11.5% of hospitalized patients with pneumonia have been found to have PIV infection. Currently no licensed treatment is available for PIV infection. Ribavirin has been used, but case studies show no impact on mortality rates. DAS181, an inhaled sialidase, is undergoing clinical development for the treatment of PIV in adults and children.

Original languageEnglish (US)
Pages (from-to)1570-1576
Number of pages7
JournalClinical Infectious Diseases
Volume65
Issue number9
DOIs
StatePublished - Nov 1 2017

Fingerprint

Paramyxoviridae Infections
Viruses
Respiratory Tract Infections
Paramyxoviridae
Ribavirin
RNA Viruses
Neuraminidase
Disease Progression
Cause of Death
Pneumonia
Pediatrics
Mortality
Therapeutics
Infection
Population

Keywords

  • DAS181
  • parainfluenza
  • pneumonia
  • ribavirin
  • vaccine

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Russell, Elliott ; Ison, Michael G. / Parainfluenza Virus in the Hospitalized Adult. In: Clinical Infectious Diseases. 2017 ; Vol. 65, No. 9. pp. 1570-1576.
@article{312d2e1ef5674794b2f2d3d4b4a7da17,
title = "Parainfluenza Virus in the Hospitalized Adult",
abstract = "Parainfluenza virus (PIV) is a negative-sense single-stranded RNA virus in the Paramyxoviridae family. There are 4 serotypes that follow seasonal patterns with varying rates of infection for each serotype. PIV is an established cause of disease and death in the pediatric and immunocompromised populations, and its impact on the hospitalized adult is becoming more apparent with the increased use of multiplex molecular assays in the clinical setting. The clinical presentation of PIV in hospitalized adults varies widely and includes upper respiratory tract infections, severe lower respiratory tract infections, and exacerbations of underlying disease; 0.2{\%}-11.5{\%} of hospitalized patients with pneumonia have been found to have PIV infection. Currently no licensed treatment is available for PIV infection. Ribavirin has been used, but case studies show no impact on mortality rates. DAS181, an inhaled sialidase, is undergoing clinical development for the treatment of PIV in adults and children.",
keywords = "DAS181, parainfluenza, pneumonia, ribavirin, vaccine",
author = "Elliott Russell and Ison, {Michael G}",
year = "2017",
month = "11",
day = "1",
doi = "10.1093/cid/cix528",
language = "English (US)",
volume = "65",
pages = "1570--1576",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "9",

}

Parainfluenza Virus in the Hospitalized Adult. / Russell, Elliott; Ison, Michael G.

In: Clinical Infectious Diseases, Vol. 65, No. 9, 01.11.2017, p. 1570-1576.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Parainfluenza Virus in the Hospitalized Adult

AU - Russell, Elliott

AU - Ison, Michael G

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Parainfluenza virus (PIV) is a negative-sense single-stranded RNA virus in the Paramyxoviridae family. There are 4 serotypes that follow seasonal patterns with varying rates of infection for each serotype. PIV is an established cause of disease and death in the pediatric and immunocompromised populations, and its impact on the hospitalized adult is becoming more apparent with the increased use of multiplex molecular assays in the clinical setting. The clinical presentation of PIV in hospitalized adults varies widely and includes upper respiratory tract infections, severe lower respiratory tract infections, and exacerbations of underlying disease; 0.2%-11.5% of hospitalized patients with pneumonia have been found to have PIV infection. Currently no licensed treatment is available for PIV infection. Ribavirin has been used, but case studies show no impact on mortality rates. DAS181, an inhaled sialidase, is undergoing clinical development for the treatment of PIV in adults and children.

AB - Parainfluenza virus (PIV) is a negative-sense single-stranded RNA virus in the Paramyxoviridae family. There are 4 serotypes that follow seasonal patterns with varying rates of infection for each serotype. PIV is an established cause of disease and death in the pediatric and immunocompromised populations, and its impact on the hospitalized adult is becoming more apparent with the increased use of multiplex molecular assays in the clinical setting. The clinical presentation of PIV in hospitalized adults varies widely and includes upper respiratory tract infections, severe lower respiratory tract infections, and exacerbations of underlying disease; 0.2%-11.5% of hospitalized patients with pneumonia have been found to have PIV infection. Currently no licensed treatment is available for PIV infection. Ribavirin has been used, but case studies show no impact on mortality rates. DAS181, an inhaled sialidase, is undergoing clinical development for the treatment of PIV in adults and children.

KW - DAS181

KW - parainfluenza

KW - pneumonia

KW - ribavirin

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=85032879137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032879137&partnerID=8YFLogxK

U2 - 10.1093/cid/cix528

DO - 10.1093/cid/cix528

M3 - Review article

C2 - 28591775

AN - SCOPUS:85032879137

VL - 65

SP - 1570

EP - 1576

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 9

ER -